Cytosorbents Corporation Common Stock (CTSO)

FairStock Score: 38/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for durable earning power and a margin of safety. Cytosorbents makes CytoSorb, a blood purification cartridge used in critical illness. It is a real commercial product with 129 employees, but the financial record does not show a self-sustaining enterprise. In fiscal 2025, the year ended 2025-12-31, revenue was $37.1 million and net loss was $8.2 million, with diluted EPS of -$0.13. That was better than fiscal 2024, when revenue was $35.6 million and net loss was $20.7 million, and fiscal 2023, when revenue was $31.1 million and net loss was $29.2 million. Still, in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $9.6 million and net loss was $4.4 million, or diluted EPS -$0.07. The comparable fiscal Q2 2025 had $9.6 million revenue and $1.9 million net income, so the latest quarter did not extend that profit. Cash generation and balance-sheet quality are pressing concerns. Trailing free cash flow is -$9.6 million, and FairStock calculates a -4.4% FCF yield on the $217.4 million market cap. FairStock also shows an Altman Z-score of -8.71 and a Piotroski F-score of 4/9, signs of financial stress. At the 2026-10-13 close of $3.46, FairStock calculates P/B of 12.45 and a negative P/E; ROE is -336.21% and ROCE is -17.12%. Recent filed comparables show little top-line expansion: fiscal Q2 2026 revenue of $9.6 million matched fiscal Q2 2025 revenue of $9.6 million. The Lynch screen fits no category because the company lost money in each of the last four years. FairStock's overall score is 38/100. A medical-device platform can offer optionality, but I see no demonstrated moat or margin of safety in these numbers.

In plain English: Cytosorbents makes a blood-filtering device called CytoSorb for people with serious illnesses. The company is still losing money and sales have grown only slowly, so the business looks weak and unproven. At the 2026-10-13 close of $3.46, the stock looks expensive compared with its current sales and losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer